Table II.
Changes in metabolic variables in 27 patients treated with pioglitazone.
| Pioglitazone treatment | |||
|---|---|---|---|
| Variables | Before | After | P-value |
| Body weight (kg) | 59.8 (39.6–83.1) | 60.3 (41.3–86.2) | 0.012 |
| FPG (mg/dl) | 117.5 (89.0–200.0) | 110.0 (80.0–159.0) | 0.007 |
| FIRI (µU/ml) | 11.3 (3.2–31.2) | 9.3 (1.8–27.7) | 0.006 |
| HOMA-IR | 3.3 (1.1–10.0) | 2.6 (0.6–7.1) | 0.002 |
| HbA1c (%) | 6.1 (4.7–8.0) | 5.6 (4.4–7.1) | 0.002 |
| Total adiponectin (µg/ml) | 8.8 (1.5–49.3) | 26.8 (3.1–60.7) | <0.001 |
| HMW adiponectin (µg/ml) | 4.3 (0.2–32.4) | 17.3 (0.9–39.1) | <0.001 |
| MMW adiponectin (µg/ml) | 1.6 (0.4–9.1) | 4.1 (0.9–12.6) | <0.001 |
| LMW adiponectin (µg/ml) | 3.7 (0.9–7.8) | 5.6 (1.4–13.0) | <0.001 |
Continuous variables ARE presented as median (range). FPG, fasting plasma glucose; FIRI, fasting immunoreactive insulin; HOMA-IR, homeostasis model assessment for insulin resistance; HbA1c, glycated hemoglobin; HMW, high-molecular-weight; MMW, middle-molecular-weight; LMW, low-molecular-weight.